东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01875 东曜药业-B

未开盘 03-26 16:08:15

5.250

-0.070

-1.32%

最高5.430	最低5.190	成交量66.62万
今开5.320	昨收5.320	日振幅4.51%
总市值40.58亿	流通市值40.57亿	总股本7.73亿
成交额351.42万	换手率0.09%	流通股本7.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01875","market":"HK","secType":"STK","nameCN":"东曜药业-B","latestPrice":5.25,"timestamp":1774512495791,"preClose":5.32,"halted":0,"volume":666200,"delay":0,"changeRate":-0.013157894736842158,"floatShares":772787887,"shares":773000000,"eps":-0.15651217107796334,"marketStatus":"未开盘","change":-0.07,"latestTime":"03-26 16:08:15","open":5.32,"high":5.43,"low":5.19,"amount":3514246,"amplitude":0.045113,"askPrice":5.29,"askSize":21200,"bidPrice":5.25,"bidSize":800,"shortable":0,"etf":0,"ttmEps":-0.1628426802735995,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":0,"adr":0,"listingDate":1573142400000,"exchange":"SEHK","adjPreClose":5.32,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0.100678,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01875","defaultTab":"news","newsList":[{"id":"1106138065","title":"异动解读 | 药明合联收购要约正式生效，东曜药业-B盘中大涨11.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106138065","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106138065?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:44","pubTimestamp":1774334696,"startTime":"0","endTime":"0","summary":"东曜药业-B今日盘中股价大幅上涨11.02%，市场表现强劲。消息面上，此次股价异动主要源于药明合联对其发起的现金要约收购已正式生效。据悉，药明合联已取得东曜药业60%股权的有效接纳，标志着此次战略整合进入新阶段。值得注意的是，协同效应已初步显现，药明合联已将部分客户订单转至东曜药业，并获得客户积极反馈，这进一步印证了市场对东曜药业ADC CDMO技术及执行效率的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01875"],"gpt_icon":0},{"id":"1180267547","title":"异动解读 | 药明合联收购要约正式生效，东曜药业-B盘中大涨11.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180267547","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180267547?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:06","pubTimestamp":1773972409,"startTime":"0","endTime":"0","summary":"东曜药业-B今日盘中大涨11.09%，引起了市场的广泛关注。消息面上，药明合联对东曜药业的现金要约收购已取得东曜药业60%股权之有效接纳，股份要约已正式生效。通过本次控股收购，药明合联将进一步丰富项目组合、扩大客户群体，增强产能配置，持续稳固在全球ADC CRDMO领域的领先地位。根据香港联交所披露的文件，WuXi XDC Cayman Inc.以每股均价4.0港元场外增持东曜药业4.64亿股普通股股份，价值约18.55亿港元。增持后，其最新持股数目为4.64亿股股份，好仓比例由0.00%大幅升至60.00%。市场认为，此次收购的顺利推进和控股权的确立，是推动股价上涨的主要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"716700f540e2f30ce9084471cdfe18ec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01875"],"gpt_icon":0},{"id":"2620205448","title":"港股异动 | 东曜药业-B(01875)再涨超11% 年内股价已翻倍 药明合联收购要约正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205448","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620205448?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:00","pubTimestamp":1773972047,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B再涨超11%，年内股价已实现翻倍，截至发稿，涨9.94%，报5.75港元，成交额2108.74万港元。消息面上，药明合联宣布，药明合联对东曜药业的现金要约收购已取得东曜药业60%股权之有效接纳，股份要约已正式生效。根据香港联交所披露的文件，3月17日，WuXi XDC Cayman Inc.以每股均价4.0港元场外增持东曜药业4.64亿股普通股股份，价值约18.55亿港元。增持后，其最新持股数目为4.64亿股股份，好仓比例由0.00%升至60.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"716700f540e2f30ce9084471cdfe18ec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1574","SG9999014674.SGD","BK1141","BK1161","02268","LU2488822045.USD","BK4585","BK4588","01875"],"gpt_icon":0},{"id":"2620292008","title":"港股异动 | 东曜药业-B(01875)涨超9% 药明合联已取得公司60%股权有效接纳 收购要约正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292008","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620292008?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:57","pubTimestamp":1773885457,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B涨超9%，截至发稿，涨8.02%，报4.85港元，成交额1989.09万港元。消息面上，3月18日，药明合联宣布，公司已成功获得东曜药业60%股权之有效接纳，本次收购要约已正式生效。据药明合联介绍，本次收购要约的最后可接纳截止日期为2026年3月31日下午4时，东曜药业股东将在剩余的时间里决策是否接纳本次要约。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","SG9999014674.SGD","LU2488822045.USD","BK4585","BK4588","02268","BK1161","BK1141","BK1574","01875"],"gpt_icon":0},{"id":"1189439423","title":"异动解读 | 业绩显示CDMO业务增长及国际化突破，东曜药业-B盘中大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189439423","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189439423?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:38","pubTimestamp":1773884339,"startTime":"0","endTime":"0","summary":"东曜药业-B今日盘中大涨5.12%，引起了市场的广泛关注。消息面上，公司于近期发布了截至2025年12月31日止的年度业绩报告。报告显示，尽管公司整体收益有所下降并录得亏损，但其CDMO业务表现亮眼，收入同比增长13%，已成为公司稳定的“压舱石”。此外，公司在战略转型与国际化方面取得重要进展。这些积极因素可能增强了市场对公司未来增长潜力的信心，从而推动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01875"],"gpt_icon":0},{"id":"2620425493","title":"东曜药业-B(01875)发布年度业绩，收益7.48亿元 战略转型CDMO成果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425493","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620425493?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:03","pubTimestamp":1773842603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 发布截至2025年12月31日止年度业绩，该集团取得收益人民币7.48亿元，同比减少31.93%;研发开支8567.5万元，同比增加8.02%;公司权益持有人应占亏损约1亿元，每股亏损0.14元。公告称，产品销售收入为4.88亿元，同比下降44%，此变化主要系市场竞争加剧。CDMO业务收入为2.35亿元，同比增长13%。全年新增项目60个，项目总数累计至213个，其中ADC相关项目占比达68%。已签约未完成订单达3.08亿元，同比增长61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","CDMO","BK1574","BK4139"],"gpt_icon":0},{"id":"1130851208","title":"东曜药业-B（01875）现金要约接纳达60%，已转为无条件 要约维持至3月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=1130851208","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130851208?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:36","pubTimestamp":1773743773,"startTime":"0","endTime":"0","summary":"东曜药业-B与药明合联生物技术有限公司17日联合公告，药明合联就东曜药业-B全部已发行股份及尚未行使购股权提出的自愿有条件现金要约，已满足所有生效条件并转为无条件。截至2026年3月17日16:00，要约人已收到涉及463,672,734股要约股份的有效接纳，占东曜药业-B已发行股本及投票权约60.00%，达到原定不少于60%的接纳条件。同时，购股权要约亦收到6,512,600份购股权的有效接纳，占未行使购股权总额约85.33%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2620449190","title":"港股异动 | 东曜药业-B(01875)午后涨超5% 药明合联收购条件到期未达成 要约期已延长","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449190","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620449190?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:23","pubTimestamp":1773732198,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B(01875)午后涨超5%，截至发稿，涨4.04%，报43.8港元，成交额815.65万港元。消息面上，今年1月，东曜药业获药明合联溢价约99%提现金要约。据悉，本次收购成功的关键在于药明合联能否在截止日期前获得至少60%的东曜药业投票权。药明合联此前已经锁定了持有42.16%股份的五大主要股东的“不可撤销承诺”。3月13日，公司公告称，由于接纳条件于首个截止日期未获达成，要约人把首个截止日期延长至2026年3月27日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1574","VXUS","BK4585","SG9999014674.SGD","BK4588","BK1141","LU2488822045.USD","BK1161","02268"],"gpt_icon":0},{"id":"1138218451","title":"药明合联(02268)收购东曜药业-B(01875)首阶段获46.54%股份接纳　要约延长至3月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=1138218451","media":"公告速递","labels":["shareholding","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138218451?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:36","pubTimestamp":1773398179,"startTime":"0","endTime":"0","summary":"药明合联生物技术有限公司与东曜药业-B13日联合公告，药明合联透过花旗环球金融亚洲有限公司按每股现金方式提出的自愿有条件全面收购及购股权注销要约，于首个截止日期已接获359,633,024股有效接纳，占东曜药业已发行股本约46.54%。\\n\\n同时，购股权要约获接纳6,512,600份，约占东曜药业截至公告日尚未行使购股权总数的85.33%。由于股份要约需达到不少于60%投票权的接纳条件，目前该条件尚未满足，股份要约及购股权要约均未生效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2618139039","title":"东曜药业-B03月12日主力净流入122.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618139039","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618139039?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:15","pubTimestamp":1773303351,"startTime":"0","endTime":"0","summary":"03月12日, 东曜药业-B股价涨10.37%，报收4.47元，成交金额1799.1万元，换手率0.54%，振幅11.60%，量比2.66。东曜药业-B今日主力资金净流入122.2万元，上一交易日主力净流出0万元。该股近5个交易日上涨10.67%，主力资金累计净流入38.8万元；近20日主力资金累计净流出728.1万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312162010a6ba445b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312162010a6ba445b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01875"],"gpt_icon":0},{"id":"2618257086","title":"【IPO前哨】诺令生物闯港股：女博士带队，光环与商业化焦虑并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2618257086","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618257086?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:48","pubTimestamp":1773046080,"startTime":"0","endTime":"0","summary":"诺令生物的核心产品iNOwill，打破了这一惯例。诺令生物对此野心勃勃，未来计划构建以iNO为核心的综合生态系统、持续拓宽心肺诊疗产品管线，并积极扩充全球业务版图。诺令生物的商业化表现，未能匹配技术领域的突破。截至2025年9月底，公司账上现金及现金等价物仅剩3001.8万元，另外还有定期存款1.41亿元。截至2025年9月底，公司负债总额达5.57亿元，负债净额达3.22亿元。对于投资者而言，诺令生物的稀缺性毋庸置疑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650512722&idx=2&sn=c7e7e4c704805537353daff787c53659&chksm=f260e83dc517612b6f939ca941b3bfd4d46c262d5c478ce0ada2eeb5d08af635fe6cafb970d8#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["01875","03696","BK1161","02627","BK1574","02315","BK1141"],"gpt_icon":0},{"id":"2617512147","title":"东曜药业-B(01875.HK)拟3月18日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2617512147","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617512147?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:07","pubTimestamp":1772701629,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨东曜药业-B(01875.HK)宣布，公司谨定于2026年3月18日(星期三)举行董事会会议，以考虑及通过本集团截至2025年12月31日止年度的全年业绩，以及处理其他事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260305/32047167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","01875","BK1574"],"gpt_icon":0},{"id":"1121059243","title":"东曜药业-B（01875）2月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1121059243","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121059243?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:47","pubTimestamp":1772700434,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司（“东曜药业-B”，股票代码：01875）于2026年3月5日公告，披露截至2026年2月28日的股份变动月报。\n报告期内公司普通股已发行股份总数由上月末的772,787,887股维持不变，期末依旧为772,787,887股，未出现新增发行、购回或注销行为，公司库藏股数量为0。注册股本无变化。\n根据公司于2013年2月20日采纳的首次公开发售前购股权计划，本月末可行使的期权数量为7,632,600份，与上月持平。\n公司确认已符合适用的公众持股量要求，并遵守香港联合交易所有限公司《上市规则》及相关法律规定。该月报由联席公司秘书吕颖一签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2616034246","title":"东曜药业-B(01875)2025年实现营业收入约7.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616034246","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616034246?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:10","pubTimestamp":1772539806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)公布，于2025年，实现营业收入约7.48亿元，同比减少31.93%;净亏损约1亿元，同比盈转亏。资产负债方面，2025 年末净资产总额约 6.26 亿元，流动负债、非流动负债同比有所下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875"],"gpt_icon":0},{"id":"1117428726","title":"东曜药业(1875)与BioDlink及药明生物发布澄清公告 重新确认未行使购股权总数","url":"https://stock-news.laohu8.com/highlight/detail?id=1117428726","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117428726?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:51","pubTimestamp":1772538664,"startTime":"0","endTime":"0","summary":"BioDlink International Company Limited、药明生物与东曜药业股份有限公司于2026年1月14日联合发布有关收购事项的公告，并于2026年2月12日联合发出相关综合文件。东曜药业股份有限公司于2026年3月1日依据收购守则规则3.8另行发布公告，随后在2026年3月3日再次发表澄清公告，以补充先前披露事宜。根据澄清公告内容，东曜药业股份有限公司董事会说明，在2026年3月1日已有142,000份购股权归属后，未行使的购股权总数现为7,632,600份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2616555824","title":"东曜药业-B(01875)：14.2万份购股权已归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2616555824","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616555824?lang=zh_cn&edition=full","pubTime":"2026-03-01 19:17","pubTimestamp":1772363835,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，于2026年3月1日，14.2万份购股权已归属。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1574","BK1161"],"gpt_icon":0},{"id":"1129568959","title":"东曜药业(1875)与BioDlink International就收购要约发布最新公告","url":"https://stock-news.laohu8.com/highlight/detail?id=1129568959","media":"公告速递","labels":["merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129568959?lang=zh_cn&edition=full","pubTime":"2026-03-01 18:16","pubTimestamp":1772360191,"startTime":"0","endTime":"0","summary":"东曜药业股份有限公司联合BioDlink International Company Limited(要约人)于2026年3月1日发布公告，披露收购相关事项最新进展，并提及此前与药明生物共同刊发的要约信息。公告依据香港公司收购及合并守则规则3.8作出，提醒相关持有人遵守相应的交易披露规定。公告显示，截至2026年3月1日，东曜药业新增归属了142,000份购股权。其次，尚未行使购股权合计7,632,600份，其中7,348,600份已归属但未行使，142,000份尚未归属。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2614078881","title":"东曜药业-B02月26日主力净流出154.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614078881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614078881?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:15","pubTimestamp":1772093716,"startTime":"0","endTime":"0","summary":"02月26日, 东曜药业-B股价跌2.87%，报收4.06元，成交金额1258.2万元，换手率0.40%，振幅3.35%，量比2.62。东曜药业-B今日主力资金净流出154.5万元，上一交易日主力净流出0万元。该股近5个交易日下跌3.33%，主力资金累计净流出314.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出494.2万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226161602a4ca9fc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226161602a4ca9fc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2611062139","title":"东曜药业-B02月12日获主力加仓104.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611062139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611062139?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884132,"startTime":"0","endTime":"0","summary":"02月12日，东曜药业-B股价收平报4.20元，成交金额1727.7万元，换手率0.53%，振幅4.05%，量比1.65。东曜药业-B今日主力资金净流入104.0万元，上一交易日主力净流入2.6万元。该股近5个交易日下跌2.10%，主力资金累计净流入78.3万元；近20日主力资金累计净流出3317.1万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161728a49b8c4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161728a49b8c4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1574","BK1161"],"gpt_icon":0},{"id":"2610710967","title":"药明合联生物技术有限公司与东曜药业股份有限公司联合公告：要约收购相关事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2610710967","media":"金吾财讯","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610710967?lang=zh_cn&edition=full","pubTime":"2026-02-12 06:43","pubTimestamp":1770849815,"startTime":"0","endTime":"0","summary":"公告指出，综合文件及随附的接纳表格将于2026年2月12日寄送给股东和购股权持有人，要约亦于同日正式启动。同时，公告提醒股东、受限制股份奖励持有人和购股权持有人，在收到综合文件及随附的接纳表格后，应仔细阅读相关内容，并根据独立财务顾问的意见及独立董事委员会的建议，审慎决定是否接受要约。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212070618a499a13a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212070618a499a13a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02268","SG9999014674.SGD","01875","BK1161","BK1574","BK1141"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.totbiopharm.com.cn","stockEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":0.2441},{"period":"3month","weight":1.1},{"period":"6month","weight":1.2926},{"period":"1year","weight":1.6119},{"period":"ytd","weight":1.1}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.0652},{"period":"3month","weight":-0.0373},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.0585},{"period":"ytd","weight":-0.0302}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东曜药业股份有限公司是一家临床阶段生物制药公司，主要从事开发及商业化肿瘤药物及疗法。该公司的主营业务在中华人民共和国从事抗肿瘤药物的研究与开发、生产及营销、合约开发生产组织（CDMO）/合约生产组织（CMOJ）业务以及自主开发生物药物的对外许可。该公司拥有针对各类癌症的在研肿瘤药物管线，当中包括单克隆抗（mAb）及抗体偶联药物（ADC）。该公司已建立起一个集发现、产程开发、质量管理临床前及临床开发以及商业规模的生产基地和销售及营销能力于一体的综合内部平台。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":0.036017},{"month":2,"riseRate":0,"avgChangeRate":-0.037884},{"month":3,"riseRate":0.571429,"avgChangeRate":0.019136},{"month":4,"riseRate":0.833333,"avgChangeRate":0.069994},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07905},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.001367},{"month":7,"riseRate":0.333333,"avgChangeRate":0.023634},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.052288},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011349},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.041625},{"month":11,"riseRate":0,"avgChangeRate":-0.064081},{"month":12,"riseRate":0.714286,"avgChangeRate":0.042078}],"exchange":"SEHK","name":"东曜药业-B","nameEN":"BIODLINK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东曜药业-B,01875,东曜药业-B股票,东曜药业-B股票老虎,东曜药业-B股票老虎国际,东曜药业-B行情,东曜药业-B股票行情,东曜药业-B股价,东曜药业-B股市,东曜药业-B股票价格,东曜药业-B股票交易,东曜药业-B股票购买,东曜药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}